Research Papers

25 of 127 papers

CSV Excel
Quick filters: Open Data Open Code Pre-registered Funding Declared COI Declared Open Access Clear Filters
Iron overload status in patients with non-transfusion-dependent thalassemia in China.
Huang Y; Yang G; Wang M; Wei X; Pan L; Liu J; Lei Y; Peng; Long L; Lai Y; Liu R.
Ther Adv Hematol (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
Mantle cell lymphoma management trends and novel agents: where are we going?
Pu JJ; Savani M; Huang N; Epner EM.
Ther Adv Hematol (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
Chimeric antigen receptor (CAR) T-cell treatment for mantle cell lymphoma (MCL).
Tbakhi B; Reagan PM.
Ther Adv Hematol (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
Improvement in pain-related quality of life in patients with hemophilia A treated with rFVIIIFc individualized prophyla…
Pasi J; Hermans C; Hakimi Z; Nazir J; Aballéa S; Ezzalfani M; Fatoye F.
Ther Adv Hematol (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
A thrombopoietin receptor agonist to rescue an unusual platelet transfusion-induced reaction in a p.V1316M-associated v…
Casari C; Favier R; Legendre P; Kauskot A; Adam F; Picard V; Lenting PT; Denis CV; Proulle V.
Ther Adv Hematol (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
Durable outcomes of double cord blood transplantation in adults with acute lymphoblastic leukemia: high-risk features f…
Yoon JH; Min GJ; Park SS; Park S; Lee SE; Cho BS; Eom KS; Kim YJ; Kim HJ; Min CK; Cho SG; Lee JW; Lee S.
Ther Adv Hematol (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
MYD88<sup>L265P</sup> and CD79B double mutations type (MCD type) of diffuse large B-cell lymphoma: mechanism, clinical …
Chen R; Zhou; Wang L; Zhu L; Ye X.
Ther Adv Hematol (Unknown)
Published: 2022
3/6 Transparent
Funding Declared
Primary central nervous system lymphoma in the United States, 1975-2017.
Lv C; Wang J; Zhou M; Xu JY; Chen B; Wan Y.
Ther Adv Hematol (Unknown)
Published: 2022
4/6 Transparent
Registered Funding Declared
Contemporary practice patterns of tyrosine kinase inhibitor use among older patients with chronic myeloid leukemia in t…
Shallis RM; Wang R; Bewersdorf JP; Zeidan AM; Davidoff AJ; Huntington SF; Podoltsev NA; Ma X.
Ther Adv Hematol (Unknown)
Published: 2021
3/6 Transparent
Funding Declared
Prophylactic management of patients with von Willebrand disease.
Franchini M; Seidizadeh O; Mannucci PM.
Ther Adv Hematol (Unknown)
Published: 2021
2/6 Transparent
Funding Declared
Association between preconditioning absolute lymphocyte count and transplant outcomes in patients undergoing matched un…
Seo J; Shin DY; Koh Y; Kim I; Yoon SS; Min Byun J; Hong J.
Ther Adv Hematol (Unknown)
Published: 2021
3/6 Transparent
Funding Declared
Current and emerging treatment options in primary mediastinal B-cell lymphoma.
Fakhri B; Ai W.
Ther Adv Hematol (Unknown)
Published: 2021
3/6 Transparent
Funding Declared
Design of an international investigator-initiated study on MOdern Treatment of Inhibitor-positiVe pATiEnts with haemoph…
Escuriola Ettingshausen C; Sidonio RF.
Ther Adv Hematol (Unknown)
Published: 2021
4/6 Transparent
Registered Funding Declared
Addition of chemotherapy to nivolumab after PD-1 inhibitor failure as bridge to allogeneic stem cell transplantation in…
Romero S; Balaguer-Roselló A; Montoro J; Beneit P; Martínez A; Ruiz C; Andreu R; Guerreiro M; Arnao M; Montava A; Vicente AI; Jarque I; Sanz J.
Ther Adv Hematol (Unknown)
Published: 2021
3/6 Transparent
Funding Declared
Features of indeterminate results of QuantiFERON-TB Gold In-Tube test in patients with haematological malignancies.
Huang CC; Jerry Teng CL; Wu MF; Lee CH; Chen HC; Huang WC.
Ther Adv Hematol (Unknown)
Published: 2021
2/6 Transparent
Funding Declared
The use of tafasitamab in diffuse large B-cell lymphoma.
Düll J; Topp M; Salles G.
Ther Adv Hematol (Unknown)
Published: 2021
2/6 Transparent
Funding Declared
The value of survival gains from therapeutic innovations for US patients with relapsed/refractory multiple myeloma.
MacEwan JP; Majer I; Chou JW; Panjabi S.
Ther Adv Hematol (Unknown)
Published: 2021
2/6 Transparent
Funding Declared
Natural-killer cell cytotoxicity as a diagnostic and prognostic marker for adult patients with secondary hemophagocytic…
Oh EJ; Yoon JH; Park KH; Bae HJ; Yun SJ; Min GJ; Park SS; Park S; Lee SE; Cho BS; Eom KS; Kim YJ; Lee S; Kim HJ; Min CK; Cho SG; Han K; Lee JW.
Ther Adv Hematol (Unknown)
Published: 2021
3/6 Transparent
Registered Funding Declared
Ferumoxytol for the treatment of iron deficiency and iron-deficiency anemia of pregnancy.
Gerb J; Strauss W; Derman R; Short V; Mendelson B; Bahrain H; Auerbach M.
Ther Adv Hematol (Unknown)
Published: 2021
2/6 Transparent
Funding Declared
The role of tazemetostat in relapsed/refractory follicular lymphoma.
von Keudell G; Salles G.
Ther Adv Hematol (Unknown)
Published: 2021
2/6 Transparent
Funding Declared
Prognostic molecular biomarkers in diffuse large B-cell lymphoma in the rituximab era and their therapeutic implication…
Papageorgiou SG; Thomopoulos TP; Katagas I; Bouchla A; Pappa V.
Ther Adv Hematol (Unknown)
Published: 2021
2/6 Transparent
Funding Declared
Assessment of thrombotic risk during long-term treatment of immune thrombocytopenia with fostamatinib.
Cooper N; Altomare I; Thomas MR; Nicolson PLR; Watson SP; Markovtsov V; Todd LK; Masuda E; Bussel JB.
Ther Adv Hematol (Unknown)
Published: 2021
4/6 Transparent
Registered Funding Declared
A novel treatment regimen of granulocyte colony-stimulating factor combined with ultra-low-dose decitabine and low-dose…
Zhu H; Yang B; Liu J; Wang B; Wu Y; Zheng Z; Ling Y.
Ther Adv Hematol (Unknown)
Published: 2021
3/6 Transparent
Funding Declared
Advances in therapeutic options for newly diagnosed, high-risk AML patients.
Doucette K; Karp J; Lai C.
Ther Adv Hematol (Unknown)
Published: 2021
3/6 Transparent
Funding Declared
Should patients receive consolidation chemotherapy before reduced intensity allogeneic hematopoietic stem cell transpla…
Byun JM; Shin DY; Koh Y; Hong J; Kim I; Yoon SS; Bang SM; Lee JO.
Ther Adv Hematol (Unknown)
Published: 2021
2/6 Transparent
Funding Declared